Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)

Korean Multiple Myeloma Working Party

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m 2 ) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935

Original languageEnglish
Pages (from-to)923-929
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Busulfan
Melphalan
Stem Cell Transplantation
Multiple Myeloma
Stomatitis
Disease-Free Survival
Prospective Studies
Transplants
Survival
Mortality
Infection
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

@article{59a8b9c6496d4d3aab58fd619e1ff8cc,
title = "Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)",
abstract = "This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m 2 ) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9{\%}) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0{\%}, including 43.5{\%} with a stringent complete response/complete response, 27.3{\%} with very good partial response, and 23.2{\%} with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3{\%}) and stomatitis (15.2{\%}). Three (3.2{\%}) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935",
author = "{Korean Multiple Myeloma Working Party} and Jung, {Sung Hoon} and Lee, {Je Jung} and Jinseok Kim and Min, {Chang Ki} and Kihyun Kim and Yunsuk Choi and Eom, {Hyeon Seok} and Joo, {Young Don} and Kim, {Sung Hyun} and Kwak, {Jae Yong} and Kang, {Hye Jin} and Lee, {Jae Hoon} and Lee, {Ho Sup} and Mun, {Yeung Chul} and Moon, {Joon Ho} and Sohn, {Sang Kyun} and Park, {Seong Kyu} and Yong Park and Shin, {Ho Jin} and Yoon, {Sung Soo}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bbmt.2018.01.004",
language = "English",
volume = "24",
pages = "923--929",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). / Korean Multiple Myeloma Working Party.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 5, 01.05.2018, p. 923-929.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)

AU - Korean Multiple Myeloma Working Party

AU - Jung, Sung Hoon

AU - Lee, Je Jung

AU - Kim, Jinseok

AU - Min, Chang Ki

AU - Kim, Kihyun

AU - Choi, Yunsuk

AU - Eom, Hyeon Seok

AU - Joo, Young Don

AU - Kim, Sung Hyun

AU - Kwak, Jae Yong

AU - Kang, Hye Jin

AU - Lee, Jae Hoon

AU - Lee, Ho Sup

AU - Mun, Yeung Chul

AU - Moon, Joon Ho

AU - Sohn, Sang Kyun

AU - Park, Seong Kyu

AU - Park, Yong

AU - Shin, Ho Jin

AU - Yoon, Sung Soo

PY - 2018/5/1

Y1 - 2018/5/1

N2 - This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m 2 ) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935

AB - This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m 2 ) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935

UR - http://www.scopus.com/inward/record.url?scp=85041640651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041640651&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.01.004

DO - 10.1016/j.bbmt.2018.01.004

M3 - Article

C2 - 29339269

AN - SCOPUS:85041640651

VL - 24

SP - 923

EP - 929

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -